Tradition Capital Management LLC Sells 1,908 Shares of Zimmer Biomet Holdings Inc (ZBH)

Tradition Capital Management LLC trimmed its holdings in Zimmer Biomet Holdings Inc (NYSE:ZBH) by 8.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 21,311 shares of the medical equipment provider’s stock after selling 1,908 shares during the quarter. Tradition Capital Management LLC’s holdings in Zimmer Biomet were worth $2,571,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Longview Partners Guernsey LTD raised its holdings in Zimmer Biomet by 17.7% during the 3rd quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after buying an additional 1,128,973 shares during the last quarter. Koch Industries Inc. raised its holdings in Zimmer Biomet by 49,697.3% during the 2nd quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after buying an additional 1,038,674 shares during the last quarter. Alyeska Investment Group L.P. raised its holdings in Zimmer Biomet by 249.3% during the 3rd quarter. Alyeska Investment Group L.P. now owns 1,019,872 shares of the medical equipment provider’s stock valued at $119,417,000 after buying an additional 727,925 shares during the last quarter. Jana Partners LLC raised its holdings in Zimmer Biomet by 16.6% during the 3rd quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock valued at $545,932,000 after buying an additional 662,497 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in Zimmer Biomet by 14.7% during the 4th quarter. American Century Companies Inc. now owns 4,777,397 shares of the medical equipment provider’s stock valued at $576,488,000 after buying an additional 612,044 shares during the last quarter. Hedge funds and other institutional investors own 86.18% of the company’s stock.

A number of equities research analysts recently commented on the stock. Goldman Sachs Group upgraded shares of Zimmer Biomet from a “sell” rating to a “neutral” rating and set a $125.00 price target for the company in a report on Tuesday, December 19th. Stifel Nicolaus upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating and upped their price objective for the stock from $120.00 to $168.00 in a report on Wednesday, January 31st. Canaccord Genuity restated a “hold” rating and issued a $132.00 price objective on shares of Zimmer Biomet in a report on Friday, January 5th. Robert W. Baird restated a “buy” rating on shares of Zimmer Biomet in a report on Wednesday, January 31st. Finally, BMO Capital Markets restated a “buy” rating and issued a $142.00 price objective on shares of Zimmer Biomet in a report on Tuesday, December 12th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $141.67.

Shares of Zimmer Biomet Holdings Inc (ZBH) opened at $115.53 on Friday. The firm has a market cap of $24,454.70, a PE ratio of 15.04, a PEG ratio of 2.12 and a beta of 1.08. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.52 and a quick ratio of 0.83. Zimmer Biomet Holdings Inc has a 1 year low of $108.03 and a 1 year high of $133.49.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $2.10. The firm had revenue of $2.07 billion for the quarter, compared to the consensus estimate of $2.03 billion. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The company’s revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.14 EPS. research analysts anticipate that Zimmer Biomet Holdings Inc will post 7.82 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Monday, January 29th. Stockholders of record on Friday, December 29th were given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.83%. The ex-dividend date of this dividend was Thursday, December 28th. Zimmer Biomet’s dividend payout ratio is presently 10.65%.

ILLEGAL ACTIVITY NOTICE: “Tradition Capital Management LLC Sells 1,908 Shares of Zimmer Biomet Holdings Inc (ZBH)” was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://sportsperspectives.com/2018/02/09/tradition-capital-management-llc-sells-1908-shares-of-zimmer-biomet-holdings-inc-zbh.html.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply